Search results
Author(s):
Rasha Al-Lamee
,
Christopher Rajkumar
,
Nazli Okumus
Added:
1 year ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA…
View more
Author(s):
Rasha Al-Lamee
,
Michael Foley
Added:
1 year ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and…
View more
Author(s):
Johanna McChord
,
Astrid Hubert
,
Udo Sechtem
,
et al
Added:
8 months ago
Author(s):
John F Beltrame
,
Peter Ong
,
Filippo Crea
Added:
1 year ago
Author(s):
Juan Carlos Kaski
,
Hiroaki Shimokawa
Added:
1 year ago
Author(s):
Shozo Sueda
,
Tomoki Sakaue
Added:
9 months ago
Author(s):
Peter Ong
,
Astrid Hubert
,
Maike Schwidder
,
et al
Added:
2 years ago
Author(s):
Marianna Fontana
Added:
1 month ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Author(s):
Gaetano Antonio Lanza
Added:
1 month ago